UsAgainstAlzheimer’s Statement on Crenezumab Trial Results

UsAgainstAlzheimer’s Statement on Crenezumab Trial Results

Washington, DC (June 16, 2022) — Today, UsAgainstAlzheimer’s Chair and co-founder George Vradenburg issued the following statement regarding the announcement that crenezumab trials did not demonstrate a statistically significant clinical benefit in people with Alzheimer’s:

“This news is a tragedy for the extended family in Columbia who carry a specific rare genetic mutation which causes early-onset Alzheimer’s and who were the focus of this trial. While the trial demonstrated clinical benefit, the results were not statistically significant. The trial also revealed no safety issues.

“Crenezumab is a first-generation drug, and the trials were first announced ten years ago in a field where scientific advancements continue to inform the development of other treatments. Science has shown there is a direct correlation between amyloid plaque on the brain and the development of Alzheimer’s. In this case, we have learned that this specific anti-amyloid treatment did not demonstrate statistically significant clinical benefit in a very small subset of the overall Alzheimer’s population.

“Multiple pharmaceutical companies continue to invest in the research and development of anti-amyloid therapies because they believe the science and see promise in these treatments for people in the early stages of Alzheimer’s. In fact, there are additional anti-amyloid treatments in the pipeline, that are already publicly reporting positive results. We appreciate Genentech’s transparency and look forward to learning more from their research to help inform future treatments.”

For further comment on the approval of treatments that offer promise to families and individuals living with Alzheimer’s, please email Jon Summers at


About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. We take on the toughest problems; bring all of “Us” together to break down barriers; advocate for research that will speed treatments to market; and drive changes that matter most to people living with the disease. We will not rest until brain-span equals lifespan - for everyone.